Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab.
Title | Subretinal fibrosis and uveitis: a spectral domain OCT study of its evolution and the minimal therapeutic effect of the off-label treatment with ranibizumab. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Symeonidis, C., Dastiridou A., Konidaris V., Brazitikos P., & Androudi S. |
Journal | Ocul Immunol Inflamm |
Volume | 22 |
Issue | 6 |
Pagination | 497-500 |
Date Published | 2014 Dec |
ISSN | 1744-5078 |
Keywords | Antibodies, Monoclonal, Humanized, Dose-Response Relationship, Drug, Fluorescein Angiography, Fundus Oculi, Humans, Male, Middle Aged, Off-Label Use, Ranibizumab, Retina, Tomography, Optical Coherence, Uveitis, Posterior, Visual Acuity |
Abstract | PURPOSE: The subretinal fibrosis and uveitis (SFU) syndrome is a rare multifocal posterior uveitis characterized by progressive subretinal fibrosis and significant visual loss.METHODS: Slit-lamp examination, dilated fundoscopy, fluorescein angiography, Spectral Domain-Optical Coherence Tomography (SD-OCT) and laboratory testing were employed.RESULTS: A 52-year-old male presented with bilateral (best-corrected visual acuity: 2/10) visual loss. Clinical examination revealed bilateral anterior uveitis with posterior synechiae and posterior uveitis. Medical workup revealed no pathologic findings. Treatment included 1 gr intravenous prednisone followed by oral prednisone, immunosuppresive therapy and three ranibizumab injections in the right eye with no improvement. One year later, there was significant subretinal fibrosis. In the second year follow-up, the picture was slightly worse, with persisting bilateral macular edema and fibrosis.CONCLUSIONS: This is the first SFU syndrome report monitored with SD-OCT. This novel imaging modality can localize the lesion level, guide the therapeutic approach and may prove helpful in assessing disease prognosis. |
DOI | 10.3109/09273948.2013.841959 |
Alternate Journal | Ocul. Immunol. Inflamm. |
PubMed ID | 24131103 |